Results demonstrated that targeted blood pressure management helped to curb the possibility of strokes. Around the same time, the company revealed data, showing promising economic outcomes for the Medtronic HeartWare HVAD System, after conducting multiple clinical studies.The analysis showed that patients, who suffered from heart failure and received the HVAD System through a less-invasive thoracotomy procedure in the LATERAL study, incurred lower hospitalization and medical supply costs than those who received a ventricular assist device (VAD) through the traditional sternotomy implant procedure. Price Performance In the past year, the Medtronic stock has gained 12.8% compared with the industry 's 7.3% growth.